Valuation: Evotec

Market Cap 87Cr 99Cr 80Cr 75Cr 141.11Cr 9.38TCr 144.04Cr 966.13Cr 373.84Cr 4.64TCr 373.46Cr 365.31Cr 16TCr P/E 2026 *
-6.9x
P/E 2027 * -25.1x
Enterprise Value 89Cr 101.09Cr 82Cr 76Cr 143.43Cr 9.54TCr 146.41Cr 981.97Cr 379.97Cr 4.71TCr 379.58Cr 371.3Cr 16TCr EV / Sales 2026 *
1.2x
EV / Sales 2027 * 1.15x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 99Cr
-0.48%+7.20%-5.65%+3.69% 4.62TCr
+2.19%+11.71%+393.31%+609.31% 3.87TCr
+2.53%+13.93%+21.38%-10.96% 3.19TCr
+1.65%+3.61%+16.04%+55.24% 3.11TCr
-4.16%-2.58%+8.94%+26.14% 2.38TCr
-0.32%+12.96% - - 1.62TCr
+1.37%+14.53%+69.64%+136.34% 1.51TCr
+1.00%+10.30%+13.31%+23.36% 1.37TCr
+3.63%+9.53%+103.97%+106.25% 1.34TCr
Average +1.57%+9.14%+77.62%+118.67% 2.56TCr
Weighted average by Cap. +0.79%+8.71%+88.75%+138.12%

Financials

2026 *2027 *
Net sales 74Cr 84Cr 68Cr 64Cr 119.36Cr 7.94TCr 121.84Cr 817.19Cr 316.21Cr 3.92TCr 315.89Cr 308.99Cr 14TCr 82Cr 93Cr 75Cr 71Cr 132.34Cr 8.8TCr 135.09Cr 906.06Cr 350.6Cr 4.35TCr 350.24Cr 342.59Cr 15TCr
Net income -11Cr -13Cr -10Cr -9.77Cr -18Cr -1.22TCr -19Cr -125.45Cr -49Cr -602.06Cr -48Cr -47Cr -2.09TCr -3.04Cr -3.47Cr -2.8Cr -2.63Cr -4.92Cr -327.29Cr -5.02Cr -34Cr -13Cr -161.76Cr -13Cr -13Cr -560.9Cr
Net Debt 1.43Cr 1.63Cr 1.32Cr 1.23Cr 2.31Cr 153.85Cr 2.36Cr 16Cr 6.13Cr 76Cr 6.12Cr 5.99Cr 263.66Cr 6.93Cr 7.91Cr 6.39Cr 5.98Cr 11Cr 745.85Cr 11Cr 77Cr 30Cr 368.62Cr 30Cr 29Cr 1.28TCr
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.906EUR
Average target price
6.443EUR
Spread / Average Target
+31.33%

Quarterly revenue - Rate of surprise